Ascendis Pharma Reports Third Quarter 2018 Financial Results

Ascendis Pharma (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon^™ technology to address significant unmet medical needs, today announced financial results for the quarter ended September 30, 2018 and released preliminary phase 1 data for TransCon CNP.

As quoted in the press release:

“To support our vision for sustainable growth, we are creating a diversified pipeline of three independent product candidates in rare endocrine diseases. We have made a major step towards this goal with three clinically-validated, high value product candidates in one therapeutic area,” said Jan Mikkelsen, Ascendis Pharma’s President and Chief Executive Officer. “With today’s positive TransCon CNP data, we are intrigued by the opportunity to establish a leadership position in treatment of numerous growth disorders by pursuing additional indications and potential treatment synergies within our endocrinology pipeline.”

He continued, “we remain focused on delivering top-line results for our pivotal phase 3 trial of TransCon hGH, while we continue to make progress towards initiation of the phase 2 trial for TransCon PTH, both key milestones anticipated in the first quarter of 2019. Additionally, we announced the formation of VISEN Pharmaceuticals to develop and commercialize our rare disease endocrinology programs in Greater China.  This progress advances our vision to build a global, fully integrated biopharma company that will deliver sustainable growth.”

Click here to read the full press release.